Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23


52P - MiRNA profile associated with the invasiveness in non-functioning pituitary adenomas


06 Oct 2021




Emiliya Nikolova


Annals of Oncology (2021) 32 (suppl_6): S1345-S1371. 10.1016/annonc/annonc740


E. Nikolova1, B. Georgieva2, S. Klenderova2, A. Elenkova2, A. Hadzhiyanev3, A. Todorova2

Author affiliations

  • 1 Medical University Sofia, Sofia/BG
  • 2 Medical University Sofia, 1431 - Sofia/BG
  • 3 University Hospital "St. Ivan Rilski", Medical University Sofia, 1431 - Sofia/BG

Abstract 52P


Non-functioning pituitary adenomas (NFPAs) account for nearly 35% of all pituitary tumours but since no hormonal hypersecretion has been observed, the diagnosis of NFPAs remains difficult. Although the NFPAs are considered benign, in a proportion of patients, tumour recurrence and invasion have been observed. So far, no biomarkers for NFPAs monitoring are available. Differentially expressed microRNAs (miRs) have been shown biomarker potential in many solid tumours. In the present study, miRs expression profiles were analysed in patients with invasive (with or without recurrence) and non-invasive NFPAs.


MiRs profiles were analysed in 12 patients with non-invasive and 8 patients with invasive NFPAs using miRCURY LNA miRNA PCR® (Qiagen). ROC curve analysis evaluated the diagnostic ability of the selected miRNAs. P<0.05 was assumed for statistically significant and was calculated using un-paired, 2-tailed Student’s t-test.


Four miRs were found differentially expressed related to invasion and recurrence of NFPAs. MiR-106a, miR-17, miR-20 were up-regulated in patients with recurrent invasive NFPAs, with an AUR> 0.9 (95% CI = 0.839-1), while miR-210 was down-regulated in invasive NFPAs compared to patients with non-invasive NFPAs.


The ability to predict tumour invasion and recurrence after the initial surgery will decrease morbidity and mortality rate in patients with NFPAs. The selected profile of miR-106a, miR-17, miR-20 and miR-210 showed biomarker potential and could be used for future miRNA – based targeted therapies.

Legal entity responsible for the study

Medical University Sofia.


Medical University Sofia, grant number D-117/24.06.2020.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.